GlaxoSmithKline
NEWS
In 2020, Vir and GlaxoSmithKline partnered to develop strategies against COVID-19. The two companies have expanded that collaboration to include work into new treatments for influenza and other respiratory viruses.
Under the terms of the deal, Sandoz is paying GSK $350 million at closing and additional milestones up to $150 million.
Less than one week after posting a positive first-look at Phase III vaccine data, Maryland-based Novavax began the rolling review process for authorization of NVX-CoV2373 in the United Kingdom, Canada and the United States.
The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
China’s Clover Biopharmaceuticals is spurning GlaxoSmithKline’s adjuvant vaccine technology in favor of one created by California-based Dynavax Technologies.
It was a busy week for clinical trial news. Read on for more information.
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate its investigational monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate COVID-19.
With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
JOBS
IN THE PRESS